Broker Recommendations Cytokinetics, Incorporated

Stocks

CYTK

US23282W6057

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 17/07/2026 BST			5-day change	1st Jan Change
80.18 ^USD	-0.22%		-5.53%	+26.19%

07-14	Cytokinetics Insider Sold Shares Worth $615,150, According to a Recent SEC Filing	MT
07-07	RBC Capital Adjusts Cytokinetics Price Target to $117 From $119, Maintains Outperform Rating	MT

Broker Recommendations

07-07	RBC Capital Adjusts Cytokinetics Price Target to $117 From $119, Maintains Outperform Rating	MT
06-29	Cytokinetics Seen Gaining From Myqorzo Momentum to Treat Heart Conditions, UBS Says	MT
06-29	UBS Upgrades Cytokinetics to Buy From Neutral, Adjusts Price Target to $115 From $69	MT
05-06	Cytokinetics' Rapid Growth of Myqorzo not Fully Priced in by Investors, RBC Says	MT
05-06	B. Riley Adjusts Price Target on Cytokinetics to $146 From $108, Maintains Buy Rating	MT
05-06	RBC Adds Speculative Risk to Outperform Rating on Cytokinetics, Lifts Price Target to $119 From $101	MT
03-19	Mizuho Raises Price Target on Cytokinetics to $100 From $84, Keeps Outperform Rating	MT
02-20	RBC Raises Price Target on Cytokinetics to $101 From $95, Keeps Outperform, Speculative Risk	MT
02-03	Truist Raises Price Target on Cytokinetics to $92 From $84, Keeps Buy Rating	MT
01-21	B. Riley Raises Price Target on Cytokinetics to $108 From $90, Keeps Buy Rating	MT
12-22	RBC Raises Price Target on Cytokinetics to $95 From $87, Keeps Outperform, Speculative Risk	MT
11-11	Cytokinetics' 2026 Aficamten Launch Could Gain From Differentiated Strategy, RBC Says	MT
11-11	RBC Raises Price Target on Cytokinetics to $87 From $82, Keeps Outperform, Speculative Risk	MT
11-10	B. Riley Adjusts Price Target on Cytokinetics to $90 From $80, Maintains Buy Rating	MT
22/09/25	B. Riley Raises Price Target on Cytokinetics to $80 From $74, Keeps Buy Rating	MT
07/08/25	Biopharma firm Cytokinetics Q2 revenue jumps	RE
29/05/25	Mizuho Cuts Price Target on Cytokinetics to $84 From $103, Keeps Outperform Rating	MT
08/05/25	B. Riley Adjusts Cytokinetics Price Target to $74 From $88, Maintains Buy Rating	MT
07/05/25	RBC Trims Price Target on Cytokinetics to $80 From $82, Keeps Outperform, Speculative Risk	MT
02/05/25	UBS Adjusts Price Target on Cytokinetics to $41 From $47, Maintains Neutral Rating	MT
17/03/25	UBS Lowers Price Target on Cytokinetics to $47 From $61, Maintains Neutral Rating	MT
28/02/25	Oppenheimer Adjusts Price Target on Cytokinetics to $96 From $98, Maintains Outperform Rating	MT
13/02/25	Morgan Stanley Upgrades Cytokinetics to Overweight From Equalweight, Adjusts Price Target to $67 From $70	MT
13/02/25	Morgan Stanley Upgrades Cytokinetics to Overweight From Equalweight, Trims Price Target to $67 From $70	MT
07/02/25	Citigroup Initiates Cytokinetics at Buy With $86 Price Target	MT